News
BMY-RT
0.6901
-42.97%
-0.5199
BUZZ-Cytokinetics jumps after FDA approves its drug for rare heart disease
Reuters · 4d ago
JW Cayman Therapeutics Extends Vector Supply Agreement with Juno
Reuters · 4d ago
BUZZ-Cytokinetics rises after FDA approves co's drug for rare heart disease 
Reuters · 4d ago
SHARES OF SOME U.S. DRUGMAKERS RISE AFTER SIGNING DRUG PRICING DEAL WITH PRESIDENT TRUMP
Reuters · 12/19 20:27
SHARES OF BRISTOL MYERS SQUIBB UP 1.8%, GILEAD SCIENCES UP 2.9%, AMGEN AND MERCK UP NEARLY 1%
Reuters · 12/19 20:27
Bristol Myers Squibb to Provide Eliquis Free to Medicaid Under U.S. Government Agreement
Reuters · 12/19 20:05
BRISTOL-MYERS SQUIBB CO: MEDICINES AVAILABLE AT DISCOUNTS ABOUT 80% OFF CURRENT LIST PRICES
Reuters · 12/19 20:05
BRISTOL-MYERS SQUIBB CO: SPECIFIC TERMS OF AGREEMENT REMAIN CONFIDENTIAL
Reuters · 12/19 20:05
TRUMP: INSURANCE COMPANIES HAVE TO MAKE LESS MONEY
Reuters · 12/19 20:02
TRUMP: INSURANCE COMPANY MEETING TO GET THEIR PRICES DOWN
Reuters · 12/19 20:01
TRUMP: JOHNSON AND JOHNSON AND FOUR OTHER COMPANIES WILL BE COMING IN NEXT WEEK, THEY'VE AGREED TO LOWEST PRICE IN WORLD
Reuters · 12/19 19:59
BRISTOL MYERS SQUIBB SAYS ITS DONATION TO STRATEGIC RESERVE WILL INCLUDE TOP SELLING BLOOD THINNER ELIQUIS
Reuters · 12/19 19:54
TRUMP: ALL PHARMA COMPANIES HAVE AGREED
Reuters · 12/19 19:28
TRUMP: UK NHS WILL PAY FAIR SHARE AND WE EXPECT OTHER EUROPEAN COUNTRIES TO DO SO, IF NOT WILL IMPOSE TARIFFS
Reuters · 12/19 19:28
TRUMP: THE 3 OF THE 17 PHARMACEUTICAL COMPANIES WHO HAVE NOT AGREED ARE COMING IN NEXT WEEK
Reuters · 12/19 19:28
BRISTOL-MYERS SQUIBB CO <BMY.N>: BERENBERG RAISES TARGET PRICE TO $57 FROM $55
Reuters · 12/18 14:49
Bristol-Myers Squibb Company to Announce Fourth Quarter 2025 Results
Reuters · 12/18 11:59
BRISTOL MYERS SQUIBB TO REPORT RESULTS FOR FOURTH QUARTER 2025 ON FEBRUARY 5, 2026
Reuters · 12/18 11:59
U.S. RESEARCH ROUNDUP-Autozone, Coursera, Lennar
Reuters · 12/18 06:42
UPDATE 3-AbbVie, several other pharma companies near MFN deal with Trump, sources say
Reuters · 12/17 20:51
More
Webull provides a variety of real-time BMY-RT stock news. You can receive the latest news about Bristol-Myers through multiple platforms. This information may help you make smarter investment decisions.
About BMY-RT
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company's pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. Its products include Empliciti, Opdivo, Sprycel, Yervoy, Eliquis, Orencia, Baraclude, Hepatitis C Franchise, Reyataz Franchise and Sustiva Franchise. It offers products for a range of therapeutic classes, which include virology, including human immunodeficiency virus (HIV) infection; oncology; immunoscience, and cardiovascular. Its products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession across the world. Its subsidiaries are Celgene Corp and MyoKardia, Inc.